72956-35-5 Usage
Description
N-Methyl Carvedilol (Carvedilol impurity) is a chemical substance that occurs as an impurity in the synthesis of Carvedilol, a nonselective β-adrenergic blocker with α1-blocking activity. It is used in the pharmaceutical industry for the development and production of Carvedilol, which is an antihypertensive medication used in the treatment of congestive heart failure.
Uses
Used in Pharmaceutical Industry:
N-Methyl Carvedilol (Carvedilol impurity) is used as a reference standard for quality control and analytical testing in the synthesis and production of Carvedilol. It helps ensure the purity, potency, and safety of the final drug product.
Additionally, it may be used in research and development for the investigation of its potential effects and interactions with Carvedilol, as well as for the development of new pharmaceutical compounds and formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 72956-35-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,9,5 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 72956-35:
(7*7)+(6*2)+(5*9)+(4*5)+(3*6)+(2*3)+(1*5)=155
155 % 10 = 5
So 72956-35-5 is a valid CAS Registry Number.
72956-35-5Relevant articles and documents
STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME
-
, (2015/03/16)
The present invention provides compounds having store overload-induced Ca2+ release (SOICR) inhibitory activity and methods for producing and using the same. In particular, compounds of the invention is of the formula: R1-X1-L-X2-R2, wherein R1, X1, L, X2, and R2 are those defined herein.
Ryanodine receptor inhibitors and methods relating thereto
-
Page/Page column 18, (2010/11/28)
The present invention provides novel ryanodine receptor type 2 (RyR2) inhibitors and methods of their use in the treatment of cardiac conditions. In general, the RyR2 inhibitors of the present invention assist in the normalization of intracellular calcium homeostasis. In certain embodiments, the RyR2 inhibitors are store-overload-induced Ca2+ release (SOICR) inhibitors that minimally inhibit or do not inhibit Ca2+-induced Ca2+ release (CICR), thereby providing beneficial effects in cardiac therapy.